- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Inflammation
Volume 2011 (2011), Article ID 231926, 6 pages
Definition of Nonresponse to Analgesic Treatment of Arthritic Pain: An Analytical Literature Review of the Smallest Detectable Difference, the Minimal Detectable Change, and the Minimal Clinically Important Difference on the Pain Visual Analog Scale
1Scribco Pharmaceutical Writing, P.O. Box 1525, Blue Bell, PA 19422, USA
2Departments of Global Health Outcomes, Epidemiology, and Clinical Development, Merck & Co., Inc., One Merck Drive, Whitehouse Station, NJ 08889, USA
Received 25 January 2011; Accepted 8 March 2011
Academic Editor: Bernhard Rintelen
Copyright © 2011 Melissa E. Stauffer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. D. Brandt, “Second-line drug therapy for osteoarthritis,” Clinical Medicine, vol. 1, no. 2, pp. 110–112, 2001.
- C. O. Bingham III, “Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis,” Cleveland Clinic Journal of Medicine, vol. 69, no. 1, pp. SI5–SI12, 2002.
- H. A. Capell, B. Konetschnik, and R. C. Glass, “Anti-inflammatory analgesic drug responders and non-responders: a clinicopharmacological study of flurbiprofen,” British Journal of Clinical Pharmacology, vol. 4, no. 5, pp. 623–624, 1977.
- J. S. Walker, R. B. Sheather-Reid, J. J. Carmody, J. H. Vial, and R. O. Day, “Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of “responders” and 'nonresponders',” Arthritis and Rheumatism, vol. 40, no. 11, pp. 1944–1954, 1997.
- D. T. Felson, J. J. Anderson, M. Boers et al., “The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials,” Arthritis and Rheumatism, vol. 36, no. 6, pp. 729–740, 1993.
- A. M. Van Gestel, M. L. L. Prevoo, M. A. Van 'T Hof, M. H. Van Rijswijk, L. B. A. Van De Putte, and P. L. C. M. Van Riel, “Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 39, no. 1, pp. 34–40, 1996.
- T. Pincus, V. Strand, G. Koch et al., “An index of the three Core Data Set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial,” Arthritis and Rheumatism, vol. 48, no. 3, pp. 625–630, 2003.
- T. Pham, D. V. Der Heijde, M. Lassere et al., “Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria,” Journal of Rheumatology, vol. 30, no. 7, pp. 1648–1654, 2003.
- M. C. Hochberg, R. D. Altman, K. D. Brandt, and R. W. Moskowitz, “Design and conduct of clinical trials in osteoarthritis: preliminary recommendations from a Task Force of the Osteoarthritis Research Society,” Journal of Rheumatology, vol. 24, no. 4, pp. 792–794, 1997.
- T. Uhlig, T. K. Kvien, and T. Pincus, “Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 972–975, 2009.
- T. Pincus, M. Bergman, T. Sokka, J. Roth, C. Swearingen, and Y. Yazici, “Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data,” Journal of Rheumatology, vol. 35, no. 8, pp. 1550–1558, 2008.
- M. N. D. Lassere, D. Van der Heijde, K. R. Johnson, M. Boers, and J. Edmonds, “Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials,” Journal of Rheumatology, vol. 28, no. 4, pp. 892–903, 2001.
- J. M. Bland and D. G. Altman, “Statistical methods for assessing agreement between two methods of clinical measurement,” Lancet, vol. 1, no. 8476, pp. 307–310, 1986.
- C. A. McHorney and A. R. Tarlov, “Individual-patient monitoring in clinical practice: are available health status surveys adequate?” Quality of Life Research, vol. 4, no. 4, pp. 293–307, 1995.
- D. E. Beaton, C. Bombardier, J. N. Katz et al., “Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference,” Journal of Rheumatology, vol. 28, no. 2, pp. 400–405, 2001.
- H. C. de Vet, C. B. Terwee, R. W. Ostelo, H. Beckerman, D. L. Knol, and L. M. Bouter, “Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change,” Health and Quality of Life Outcomes, vol. 4, article 54, 2006.
- H. Beckerman, M. E. Roebroeck, G. J. Lankhorst, J. G. Becher, P. D. Bezemer, and A. L. M. Verbeek, “Smallest real difference, a link between reproducibility and responsiveness,” Quality of Life Research, vol. 10, no. 7, pp. 571–578, 2001.
- O. Hägg, P. Fritzell, and A. Nordwall, “The clinical importance of changes in outcome scores after treatment for chronic low back pain,” European Spine Journal, vol. 12, no. 1, pp. 12–20, 2003.
- K. W. Wyrwich, “Minimal important difference thresholds and the standard error of measurement: is there a connection?” Journal of Biopharmaceutical Statistics, vol. 14, no. 1, pp. 97–110, 2004.
- G. Rohekar and J. Pope, “Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis,” Journal of Rheumatology, vol. 36, no. 10, pp. 2178–2182, 2009.
- F. Gaston-Johansson, “Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices,” Journal of Pain and Symptom Management, vol. 12, no. 3, pp. 172–181, 1996.
- N. Athale, A. Sturley, S. Skoczen, A. Kavanaugh, and L. Lenert, “A web-compatible instrument for measuring self-reported disease activity in arthritis,” Journal of Rheumatology, vol. 31, no. 2, pp. 223–228, 2004.
- N. Bellamy, J. Campbell, and J. Syrotuik, “Comparative study of self-rating pain scales in rheumatoid arthritis patients,” Current Medical Research and Opinion, vol. 15, no. 2, pp. 121–127, 1999.
- J. E. Pope, D. Khanna, D. Norrie, and J. M. Ouimet, “The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials,” Journal of Rheumatology, vol. 36, no. 2, pp. 254–259, 2009.
- N. Bellamy, J. Campbell, and J. Syrotuik, “Comparative study of self-rating pain scales in osteoarthritis patients,” Current Medical Research and Opinion, vol. 15, no. 2, pp. 113–119, 1999.
- E. W. Ehrich, G. M. Davies, D. J. Watson, J. A. Bolognese, B. C. Seidenberg, and N. Bellamy, “Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire and global assessments in patients with osteoarthritis,” Journal of Rheumatology, vol. 27, no. 11, pp. 2635–2641, 2000.
- K. Gottesdiener, T. Schnitzer, C. Fisher et al., “Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis,” Rheumatology, vol. 41, no. 9, pp. 1052–1061, 2002.
- M. Faucher, S. Poiraudeau, M. M. Lefevre-Colau, F. Rannou, J. Fermanian, and M. Revel, “Assessment of the test-retest reliability and construct validity of a modified Lequesne index in knee osteoarthritis,” Joint Bone Spine, vol. 70, no. 6, pp. 520–525, 2003.
- J. Zacher, D. Feldman, R. Gerli et al., “A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis,” Current Medical Research and Opinion, vol. 19, no. 8, pp. 725–736, 2003.
- F. Tubach, P. Ravaud, G. Baron et al., “Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement,” Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 29–33, 2005.
- R. Jaeschke, J. Singer, and G. H. Guyatt, “Measurement of health status. Ascertaining the minimal clinically important difference,” Controlled Clinical Trials, vol. 10, no. 4, pp. 407–415, 1989.
- G. H. Guyatt, D. Osoba, A. W. Wu et al., “Methods to explain the clinical significance of health status measures,” Mayo Clinic Proceedings, vol. 77, no. 4, pp. 371–383, 2002.
- H. C. W. De Vet, R. W. J. G. Ostelo, C. B. Terwee et al., “Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach,” Quality of Life Research, vol. 16, no. 1, pp. 131–142, 2007.